China GDP grows 5% in Q1, beats expectations on exports, spending strength
Investing.com - Truist Securities raised its price target on Gilead Sciences Inc. (NASDAQ:GILD) to $155 from $152 while maintaining a Buy rating on the stock. The stock currently trades at $139.92, near InvestingPro’s Fair Value of $140.07, suggesting the shares are fairly valued. The biotechnology giant has delivered a strong 38% return over the past year and maintains an 11-year dividend growth streak. For investors seeking deeper insights, GILD is among 1,400+ US equities covered by comprehensive Pro Research Reports.
The firm anticipates an in-line first quarter 2026 for Gilead, with estimated total revenue of $6.94 billion compared to consensus of $6.91 billion and non-GAAP earnings per share of $1.84 versus consensus of $1.90.
For key commercial franchises, Truist estimates first quarter 2026 Biktarvy sales of $3.30 billion compared to consensus of $3.34 billion and Yeztugo sales of $167 million versus consensus of $151 million. The firm also forecasts Trodelvy sales of $376 million compared to consensus of $356 million and Yescarta sales of $327 million versus consensus of $352 million.
Truist adjusted anitocel’s potential late-2026 launch and out-year sales numbers and Gilead’s profit shares, reflecting the Arcellx transaction.
The firm said it will look for management commentary on Yeztugo launch strategy and payer access dynamics in U.S. and EU markets, anito-cel launch preparation updates ahead of the December 23, 2026 PDUFA date, a discussion on recent M&A activities including Ouro and Tubulis, and additional near-term growth levers including Livdelzi in PBC amid evolving competition.
In other recent news, Gilead Sciences has been actively involved in significant acquisition activities, announcing three major deals totaling approximately $15 billion. The acquisitions include the $7.8 billion purchase of Arcellx, a $1.8 billion co-acquisition of Ouro Medicines with GLPG, and a $5 billion acquisition of Tubulis. These strategic moves have prompted TD Cowen to reiterate a Buy rating with a $160 price target, while BMO Capital maintains an Outperform rating with a $174 price target, highlighting the Tubulis acquisition as a key factor. Oppenheimer also reiterated an Outperform rating, noting the acquisition strategy as a positive development.
In addition to its acquisition activities, Gilead’s Yeztugo product is drawing attention, with Cantor Fitzgerald expecting a revenue beat at $185 million, which could see further upside. RBC Capital raised its price target for Gilead to $123 from $118, citing strong tracking of third-party Yeztugo scripts and sales. Analysts suggest that the shift to greater buy-and-bill practices might be underestimating the product’s uptake. These recent developments underscore Gilead’s strategic focus on expanding its portfolio and strengthening its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.